|
Vision, TIME-ZZZ, clinical trials, and more.
|
Thank you for reading our monthly newsletter. This month’s edition is
1,660 words, about a
6-minute read.
|
|
Want to get the Elysium Newsletter in your inbox? Sign up
here.
|
|
|
|
|
|
The year is coming to a close, which means we’re reflecting on the last 12 months and gathering our energy for 2025—Elysium’s 10th anniversary! From launching
Vision for eye longevity, to initiating our TIME-ZZZ sleep and biological aging study, to publishing three new scientific papers, we’ve been fulfilled in the drive forward with our mission to improve human healthspan and lifespan by providing direct access to breakthroughs in longevity science. Before we dive into 2025, join us to recap Elysium’s top milestones from the year. Thank you to all of you for joining us on this journey to live our healthiest lives possible, for longer. We wish you a happy and healthy New Year.
|
|
|
|
|
|
Elysium CEO Eric Marcotulli reflects on 2024—and looks to the future
|
|
|
|
|
|
|
“As we approach Elysium’s 10th anniversary in 2025, I’m incredibly proud of everything we’ve accomplished as a team. When we launched
Basis almost 10 years ago, it was unprecedented to build products based on longevity science. Now longevity is a shared health aspiration and an ever-growing field of scientific research.
Vision stands out to me as a major highlight from 2024, including the opportunity to partner with Dr. Theodore Leng of Stanford University School of Medicine to deliver a truly innovative product for eye health and performance at every stage of life. We had many successes on the research front, including publishing two human clinical trials that contributed meaningfully to longevity science, one related to NAD+ supplementation and the other related to reduction of Hcy. Finally, it continues to be an honor to work with our research partners and members of our Scientific Advisory Board, several of whom were recognized this year as top researchers in the world. Elysium’s continued commitment in 2025 is to keep helping people access, understand, and benefit from scientific breakthroughs in longevity.”
|
|
|
|
|
|
|
|
|
|
Elysium launches Vision for eye longevity, performance, and protection
|
|
|
|
|
|
|
In October, only two months ago, we introduced
Vision for eye longevity, performance, and protection. We developed this breakthrough in eye care with the guidance of
Theodore Leng, M.D., Director of Clinical and Translational Research at the Byers Eye Institute at Stanford University School of Medicine. Vision enhances your visual performance by increasing contrast sensitivity, protects your eyes from high-energy blue light and oxidative stress, and restores the age-related loss of macular pigment density. This translates directly to support for your daily tasks and performance-oriented activities while targeting a key aspect of aging in the eyes.
“There is no better formulation than Vision for eye health—leveraging 20 years of data behind the AREDS studies and the latest breakthroughs in xanthophyll research,” Dr. Leng said of our collaboration.
|
|
|
|
|
|
|
|
|
|
|
|
Research update: New Elysium studies drive longevity science forward
|
|
This year we published three papers in peer-reviewed journals and gathered preliminary data that we plan to publish in 2025.
|
|
Homocysteine levels and rate of aging
|
|
A research collaboration between Elysium and the University of Oxford found significant associations between homocysteine levels and rate of aging, suggesting that individuals with high levels of homocysteine age at a faster rate. In the study, Index revealed a deceleration in biological aging in these participants following treatment with a specific combination of homocysteine-lowering B vitamins, developed at the University of Oxford and found in our brain health product
Matter. The results indicate that elevated homocysteine is causally associated with accelerated biological aging, and it’s the first research to suggest that this trend can be reversed. (Aging Cell)
|
|
Nicotinamide riboside and COPD
|
|
Chronic obstructive pulmonary disease (COPD) is a progressive, incurable disease associated with smoking and advanced age, ranking as the third leading cause of death worldwide. In this study, a collaboration with researchers at University of Copenhagen and funded by a grant from the Danish government, we evaluated the effect of Elysium’s proprietary nicotinamide riboside (NR-E) on clinical outcomes in elderly patients with COPD. The study results showed that NR-E supplementation supported a healthy inflammation response in the lungs. (Nature Aging)
|
|
NRPT in a preclinical model of sun exposure
|
|
A research collaboration between Elysium Health and Weill Cornell Medicine published a study demonstrating the synergistic benefits of nicotinamide riboside (NR) and pterostilbene (PT)—the two ingredients in
Basis—in a preclinical model of sun exposure. NR and PT together reduced tissue swelling and immune suppression more than either alone.
Dr. Richard Granstein, chair of the Department of Dermatology at Weill Cornell Medicine and Elysium Health Scientific Advisory Board member, served as the principal investigator. Further research is required to determine if these benefits can be extended to humans. (Photodermatology, Photoimmunology & Photomedicine)
|
|
Long-term use of Basis or Signal is associated with slower biological aging
|
|
Taking
Basis consistently for two or more years was associated with a ~5% slower rate of aging, according to epigenetic data, including from our TIME-A longevity study.* These individuals with a slower overall rate of aging also had slower rates of aging of the liver, kidneys, inflammation, and metabolic systems. We saw a similar ~5% reduction in the rate of aging associated with the use of
Signal for one or more years. We look forward to sharing the full results when we publish the study in 2025.
|
|
*The epigenetic data came from 473 study participants who self-reported their supplement use. Biological age can also be influenced by various environmental and lifestyle factors and changes.
|
|
|
|
|
|
|
|
|
|
Expert webinar series launches with three longevity scientists
|
|
|
|
|
|
|
This year we shared the wisdom of our Scientific Advisory Board members with our community by launching an expert webinar series. In recent months we offered three free presentations and follow-up Q&As with sleep expert and professor of circadian neuroscience at the University of Oxford
Russell Foster, Ph.D., leading retinal specialist and ophthalmologist
Theodore Leng, M.D., and
Leonard Guarente, Ph.D., co-founder of Elysium Health and renowned longevity researcher. The 2025 lineup will include presentations covering nutrition, performance, skin health, and more, plus a fireside chat with Dr. Guarente and Elysium co-founder and CEO Eric Marcotulli in honor of our 10th anniversary. In the meantime, you can now watch Dr. Guarente’s
Q&A, and rewatch any of the webinars on-demand, using the link below.
|
|
|
|
|
|
|
|
|
|
|
|
TIME-ZZZ sleep and biological aging study
|
|
|
|
|
|
|
In July, we began enrolling Index users in TIME-ZZZ, a groundbreaking study that aims to advance our understanding of the associations between chronotype, sleep quality, mental health, and biological aging. Early insights from the study suggest a potential association between social jet lag (misalignment between an individual’s circadian rhythm and their socially imposed schedule) and
biological age. TIME-ZZZ, or the Translational Initiative to Map Epigenetics in Sleep, is the second longitudinal study under the auspices of Elysium’s
Aging Research Center.
Russell Foster, Ph.D., and Elysium’s VP of bioinformatics, Dayle Sampson, Ph.D., are co-principal investigators of TIME-ZZZ. Dr. Foster serves as Professor of Circadian Neuroscience and Head of the Department of Ophthalmology at the University of Oxford, and he is a member of the Elysium Scientific Advisory Board. There’s still time to enroll in TIME-ZZZ—and all
Index users are eligible.
|
|
|
|
|
|
|
|
|
|
|
|
Scientific Advisory Board updates: A welcome and a celebration
|
|
|
|
|
|
|
In 2024, we welcomed
Mark Sarzynski, Ph.D., to our Scientific Advisory Board. Dr. Sarzynski is an Associate Professor of Exercise Science in the Arnold School of Public Health at the University of South Carolina and Director of the HERITAGE Family Study. His research focuses on the effects of lifestyle—particularly exercise—on cardiometabolic health and disease, and identifying the molecular transducers underlying individual differences in response to lifestyle interventions. Several other members of the Board were honored this year as the world’s most
highly cited researchers. Each authored multiple papers that rank in the top 1% by citations for their field and publication year over the past decade, and only about 1 in 1,000 researchers worldwide qualified. Included in this prestigious list are
Carolyn Bertozzi, Ph.D.,
Martin Blaser, M.D.,
Dariush Mozaffarian, M.D., Dr.P.H.,
Meir Stampfer, M.D., Dr.P.H., and
Thomas Südhof, Ph.D. Please join us in congratulating them!
|
|
|
|
|
|
|
|
|
|
|
|
2024 highlights from around the media
|
|
|
|
|
|
|
This year
Women’s Health said that longevity is replacing wellness as the new “it” word. Why?
“It’s health and wellness, but with staying power,” they wrote. The stories about longevity and Elysium in 2024 support this idea. We appreciate all the journalists who tried our breakthrough supplements, wrote about longevity science, and interviewed members of our team.
|
|
Among the year’s highlights were a story including
Index and heart system ages in
The Wall Street Journal,
GQ writing that
“Elysium introduced the world to the concept of cellular health,” and Dr. Guarente being interviewed for the
The TODAY Show. From
Elle to
VOGUE to
Town & Country, and everyone we haven’t specifically mentioned, we valued all of the coverage—thank you!
|
|
|
|
|
|
|
|
|
|
2025 preview: Something exciting Is on the way!
|
|
|
|
|
|
|
As we ring in our 10th anniversary next year, we intend to pause for celebration—but not for very long! Following
Vision, TIME-ZZZ, and research milestones in 2024, (on the heels of
Mosaic, new
Index measures, TIME-A, and the Aging Research Center in 2023), if you can believe it, there’s still much more to come in 2025!
|
|
|
|
|
|
|
Share your healthy aging breakthroughs
|
|
|
|
|
We’d love to hear from you! If you have a story to share about your experience with Elysium products, we want to celebrate your health journey. Please email
care@elysiumhealth.com and your story may be featured in an upcoming newsletter or on our social media channels.
|
|
|
|
|
|
